MWNA
PRVB

Marshall Wace North America’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Marshall Wace North America’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,356
Closed -$182K – 1898
2021
Q1 		$182K Sell
17,356
-412,085
-96% -$5.8M ﹤0.01% 1417
2020
Q4 		$7.28M Sell
429,441
-69,354
-14% -$1.04M 0.03% 453
2020
Q3 		$6.4M Buy
498,795
+25,889
+5% +$327K 0.04% 352
2020
Q2 		$6.67M Buy
+472,906
New +$5.97M 0.04% 328
2019
Q4 		– Sell
-200,314
Closed -$1.37M – 1696
2019
Q3 		$1.37M Buy
+200,314
New +$2.03M 0.01% 627

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Marshall Wace North America's PRVB Position: Q2 2021 in Review

Marshall Wace North America sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2021, closing a stake of 17,356 shares — an estimated $182K sold.

Marshall Wace North America first reported a position in PRVB in Q3 2019 and held it in 5 quarters. The position peaked at $7.28M in Q4 2020. 125 funds tracked by Wall St. Rank hold PRVB as of Q2 2021.

  • Marshall Wace North America reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 17,356 Provention Bio, Inc. Common Stock shares in Q2 2021, an estimated $182K.
  • Marshall Wace North America first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Marshall Wace North America's Provention Bio, Inc. Common Stock position peaked at $7.28M in Q4 2020.
  • 125 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.